Agenus Inc

Proposal 2 asks shareholders to approve an amendment to the Company’s 2019 Employee Stock Purchase Plan to increase the authorized share reserve by 50,000 shares (from 150,000 to 200,000). Management frames this as a practical, low-dilution request to sustain a broadly used employee benefit and notes the existing pool has been largely consumed due to participation and historically higher share price. The Board argues the ESPP promotes employee ownership and retention and is administered to meet Section 423 tax-qualified rules; the requested increase is positioned as necessary to avoid interruption of the program. Approving the amendment would preserve the Company’s ability to offer discounted, periodic purchase periods and maintain an alignment mechanism used in lieu of higher cash compensation. Key risks for investors are modest incremental dilution and the possibility the expanded program increases share overhang, but management contends the incremental 50,000 shares is small relative to outstanding shares and necessary to sustain workforce participation. The proposal is routine governance-level equity administration rather than a compensation change for executives; the Board recommends FOR because of employee retention, morale, and alignment benefits and because the ESPP is standard practice for public companies. If rejected, the Company may be forced to suspend or curtail the program, which could affect recruitment and retention.

Proposal 3 requests shareholder approval to increase the 2019 EIP share pool by 5,000,000 shares (≈12% of outstanding shares) to fund near-term obligations including payment of 2025 bonuses in options, 2026–2027 annual grants, inducement awards for key hires, and ongoing equity elections by executives. Management frames the increase as essential to retain talent during execution of the BATTMAN Phase 3, to preserve cash by using equity rather than cash, and to avoid creating separate ad hoc plans. The board discloses metrics on current outstanding options, burn rate and remaining shares, and emphasizes governance safeguards (no discounted options, no repricing without shareholder approval, minimum vesting, limits on director awards, no liberal share recycling) to limit shareholder dilution and misuse. Key investor considerations include near-term dilution and overhang vs. the operational need to maintain a motivated workforce through clinical and regulatory milestones; management argues the increase is sized prudently relative to needs and peer practice. The proposal is management-driven and the board recommends FOR because insufficient shares would force trade-offs that could jeopardize execution and retention.

Proposal 4 requests approval for a one-time, automatic, one-for-one exchange of eligible underwater options for new options with a tiered strike: executives and non-employee directors receive replacement options struck at 150% of the Exchange Date closing price (Tier 1), while all other eligible employees and consultants receive replacement options struck at 100% of the Exchange Date closing price (Tier 2). Management argues the exchange restores meaningful retention and incentive value across the organization without increasing the aggregate option count, and that the 150% premium for directors and executives aligns senior stakeholders with shareholder upside by requiring ≈50% stock appreciation before Tier 1 holders realize value. The proposal trades immediate dilution (none in option count, but potential future dilution upon exercise) and accounting expense for restored incentive value and retention; critics might argue management and directors still benefit and that large-scale exchanges can re-price historic grants. The board recommends FOR, citing operational milestones, the need to retain staff for Phase 3 execution and filings, and the compensating 150% executive/director premium.

Proposal 5 is a non-binding advisory approval of 2025 named executive officer compensation, presented in the context of an equity-heavy, cash-preserving program. Management emphasizes base salaries were unchanged, bonuses were paid in options to conserve cash, and meaningful realized compensation is equity-based (including executive elections to receive salary/bonuses in stock/options) to align pay with long-term shareholder returns. The Board cites the achievement of clinical, regulatory and commercial milestones, reduced burn and strategic transactions as justification for their compensation decisions. For investors evaluating governance, considerations include the pay-for-performance linkage via equity, potential dilution from equity awards, and the advisory (non-binding) nature of the vote; the Board will consider the result when setting future pay.